Category - Markets

Markets

Cantor starts Theratechnologies at OW; PT $9

Cantor Fitzgerald launched coverage of Theratechnologies (NASDAQ:THTX) with an “overweight” rating and $9 price target. The stock closed at $1.88 on Nov. 16. “We believe the peak sales potential of Theratechnologies’...

November 17, 2022

Markets

HCW ups Syros PT on optimism about AML data at ASH

H.C Wainwright raised its price target for Syros Pharmaceuticals (NASDAQ:SYRS) to $20 from $6, noting that the company’s tamibarotene “looks to shine during ASH ‘22” in December. The stock closed at $3.66 on Nov. 14...

November 15, 2022

Markets

SVB cuts Satsuma to MP after negative SUMMIT data

SVB Securities downgraded Satsuma Pharmaceuticals (NASDAQ:STSA) to “market perform” from “outperform” and slashed its price target to $1 from $15 after the company reported negative data for the Phase 3 SUMMIT trial of...

November 15, 2022

Markets

WB starts Janux Therapeutics at OP

William Blair initiated coverage of Janux Therapeutics (NASDAQ:JANX) with an “outperform” rating based on the potential of the company’s TRACTr platform, which facilitates the generation of conditionally active T-cell...

November 14, 2022

Markets

BTIG cuts OncoSec to neutral on updated Phase 2 results

BTIG downgraded OncoSec Medical (NASDAQ:ONCS) to “neutral” from “buy” and removed its price target after the company reported updated Phase 2 Keynote-695 study results. The stock closed at $4.66 on Nov. 11. Analyst...

November 14, 2022

Markets

Leede Jones Gable cuts Medical Facilities to hold on EBITDA margins

Leede Jones Gable downgraded Medical Facilities (TSX:DR) to “hold” from “buy” and lowered its price target to $9.25 (Canadian) from $12, citing solid top-line data in the third quarter of 2022, offset by cost pressures...

November 11, 2022

Markets

Maxim ups Reviva PT to $10 on rising Phase 3 enrollment

Maxim Group raised its price target for Reviva Pharmaceuticals (NASDAQ:RVPH) to $10 from $3 after the company’s ongoing Phase 3 study in schizophrenia reached more than 30% enrollment, of total 400 patients, at sites in...

November 1, 2022

Markets

Cantor starts Mainz Biomed at OW; PT $15

Cantor Fitzgerald launched coverage of Mainz Biomed B.V. (NASDAQ:MYNZ) with an “overweight” rating and 12-month price target of $15. The stock closed at $6.63 on Oct. 24. MYNZ develops market-ready molecular genetic...

October 25, 2022

Markets

Canaccord cuts T2 Biosystems to hold on Q3 results and guidance

Canaccord Genuity Capital Markets downgraded T2 Biosystems (NASDAQ:TTOO) to “hold” from “buy” and slashed its price target to $2.50 from $12.50, adjusted for the recent 1-for-50 reverse stock split after the company...

October 14, 2022

Markets

Jefferies starts SI-BONE at buy; PT $20

Jefferies launched coverage of SI-BONE (NASDAQ:SIBN) with a “buy” rating and $20 price target. The stock closed at $15.71 on Oct. 11. SI-BONE is the current market and innovation leader in sacropelvic spine surgery...

October 12, 2022

Category - Markets

Subscribe